Cara Therapeutics Yönetim
Yönetim kriter kontrolleri 2/4
Cara Therapeutics CEO'su Chris Posner, Nov2021 tarihinde atandı, in görev süresi 6.25 yıldır. in toplam yıllık tazminatı $ 2.92M olup, şirket hissesi ve opsiyonları dahil olmak üzere 24.9% maaş ve 75.1% ikramiyelerden oluşmaktadır. şirketin hisselerinin 0.22% ine doğrudan sahiptir ve bu hisseler $ 36.68K değerindedir. Yönetim ekibinin ve yönetim kurulunun ortalama görev süresi sırasıyla 3 yıl ve 5.3 yıldır.
Anahtar bilgiler
Chris Posner
İcra Kurulu Başkanı
US$2.9m
Toplam tazminat
| CEO maaş yüzdesi | 24.9% |
| CEO görev süresi | 3yrs |
| CEO sahipliği | 0.2% |
| Yönetim ortalama görev süresi | 3yrs |
| Yönetim Kurulu ortalama görev süresi | 5.3yrs |
Son yönetim güncellemeleri
Recent updates
Cara Therapeutics, Inc.'s (NASDAQ:CARA) Share Price Is Matching Sentiment Around Its Revenues
Nov 01
Cara Therapeutics, Inc.'s (NASDAQ:CARA) Price Is Right But Growth Is Lacking After Shares Rocket 34%
Jul 18We Think Cara Therapeutics, Inc.'s (NASDAQ:CARA) CEO Compensation Package Needs To Be Put Under A Microscope
May 29Why Investors Shouldn't Be Surprised By Cara Therapeutics, Inc.'s (NASDAQ:CARA) Low P/S
May 25We're A Little Worried About Cara Therapeutics' (NASDAQ:CARA) Cash Burn Rate
Feb 16The Market Doesn't Like What It Sees From Cara Therapeutics, Inc.'s (NASDAQ:CARA) Revenues Yet As Shares Tumble 43%
Dec 19News Flash: Analysts Just Made A Notable Upgrade To Their Cara Therapeutics, Inc. (NASDAQ:CARA) Forecasts
Nov 04Can Cara Therapeutics (NASDAQ:CARA) Afford To Invest In Growth?
Oct 25Is Cara Therapeutics (NASDAQ:CARA) In A Good Position To Deliver On Growth Plans?
Jul 20Take Care Before Jumping Onto Cara Therapeutics, Inc. (NASDAQ:CARA) Even Though It's 30% Cheaper
Jun 04News Flash: 8 Analysts Think Cara Therapeutics, Inc. (NASDAQ:CARA) Earnings Are Under Threat
Mar 11Cara Therapeutics, Inc. (NASDAQ:CARA) Analysts Just Slashed Next Year's Estimates
Feb 15We Think Cara Therapeutics (NASDAQ:CARA) Can Afford To Drive Business Growth
Feb 06We're Interested To See How Cara Therapeutics (NASDAQ:CARA) Uses Its Cash Hoard To Grow
Oct 18Cara's partner files for Japanese approval of Korsuva to treat itch in hemodialysis patients
Sep 28Cara Therapeutics hires new finance chief
Sep 12Cara Therapeutics: All Eyes On Korsuva Launch Metrics
Sep 01Cara, Vifor's Kapruvia gets approval in Switzerland to treat itch in hemodialysis patients
Aug 19Cara Therapeutics GAAP EPS of -$0.08 beats by $0.18, revenue of $23M beats by $1.97M
Aug 08Calls A Much Safer Way To Buy Cara Therapeutics
Jun 24We're Not Very Worried About Cara Therapeutics' (NASDAQ:CARA) Cash Burn Rate
Jun 15Brokers Are Upgrading Their Views On Cara Therapeutics, Inc. (NASDAQ:CARA) With These New Forecasts
May 12Taking A (Speculative) Position In Cara Therapeutics
Mar 21Companies Like Cara Therapeutics (NASDAQ:CARA) Are In A Position To Invest In Growth
Mar 09Cara Therapeutics: De-Risked And Extremely Attractive
Dec 25Checking Back In On Cara Therapeutics
Nov 01Cara And IV Korsuva: Key Bull And Bear Investor Thoughts Going Into Upcoming PDUFA
Aug 21The Consensus EPS Estimates For Cara Therapeutics, Inc. (NASDAQ:CARA) Just Fell Dramatically
Aug 15Cara Therapeutics: 200% Upside Possible With FDA Approval
Aug 11CEO Tazminat Analizi
| Tarih | Toplam Tazminat | Maaş | Şirket Kazançları |
|---|---|---|---|
| Sep 30 2024 | n/a | n/a | -US$96m |
| Jun 30 2024 | n/a | n/a | -US$111m |
| Mar 31 2024 | n/a | n/a | -US$123m |
| Dec 31 2023 | US$3m | US$728k | -US$119m |
| Sep 30 2023 | n/a | n/a | -US$117m |
| Jun 30 2023 | n/a | n/a | -US$112m |
| Mar 31 2023 | n/a | n/a | -US$84m |
| Dec 31 2022 | US$3m | US$700k | -US$85m |
| Sep 30 2022 | n/a | n/a | -US$89m |
| Jun 30 2022 | n/a | n/a | -US$66m |
| Mar 31 2022 | n/a | n/a | -US$93m |
| Dec 31 2021 | US$10m | US$116k | -US$88m |
| Sep 30 2021 | n/a | n/a | US$24m |
| Jun 30 2021 | n/a | n/a | US$8m |
| Mar 31 2021 | n/a | n/a | US$14m |
| Dec 31 2020 | US$280k | n/a | US$8m |
| Sep 30 2020 | n/a | n/a | -US$99m |
| Jun 30 2020 | n/a | n/a | -US$115m |
| Mar 31 2020 | n/a | n/a | -US$113m |
| Dec 31 2019 | US$302k | n/a | -US$106m |
| Sep 30 2019 | n/a | n/a | -US$98m |
| Jun 30 2019 | n/a | n/a | -US$85m |
| Mar 31 2019 | n/a | n/a | -US$79m |
| Dec 31 2018 | US$494k | n/a | -US$74m |
Tazminat ve Piyasa: Chris 'nin toplam tazminatı ($USD 2.92M ), US pazarındaki benzer büyüklükteki şirketler için ortalamanın üzerindedir ($USD 652.28K ).
Tazminat ve Kazançlar: Chris şirketinin tazminatı, şirket kârsız olduğu sürece artırıldı.
CEO
Chris Posner (54 yo)
3yrs
Görev süresi
US$2,922,469
Tazminat
Mr. Christopher A. Posner also known as Chris, served as Independent Director of Zevra Therapeutics, Inc. (formerly known as KemPharm, Inc.), since November 2022. He serves as President and Chief Executive...
Liderlik Ekibi
| İsim | Pozisyon | Görev süresi | Tazminat | Sahiplik |
|---|---|---|---|---|
| President | 3yrs | US$2.92m | 0.22% $ 36.7k | |
| Chief Financial Officer | 2.2yrs | US$1.24m | 0.015% $ 2.4k | |
| Co-Founder & Senior Advisor | 3yrs | US$10.20m | Veri yok | |
| Chief Compliance Officer | 8yrs | US$1.59m | 0.15% $ 24.9k | |
| Manager of Investor Relations | no data | Veri yok | Veri yok |
3.0yrs
Ortalama Görev Süresi
57.5yo
Ortalama Yaş
Deneyimli Yönetim: CARA 'un yönetim ekibi deneyimli olarak değerlendirilmektedir (ortalama görev süresi 3 yıldır).
Yönetim Kurulu Üyeleri
| İsim | Pozisyon | Görev süresi | Tazminat | Sahiplik |
|---|---|---|---|---|
| President | 6.3yrs | US$2.92m | 0.22% $ 36.7k | |
| Independent Chairman & Lead Independent Director | 14.3yrs | US$519.99k | 0.20% $ 33.5k | |
| Member of the Scientific Advisory Board | no data | Veri yok | Veri yok | |
| Member of the Scientific Advisory Board | no data | Veri yok | Veri yok | |
| Member of the Scientific Advisory Board | no data | Veri yok | Veri yok | |
| Member of the Scientific Advisory Board | no data | Veri yok | Veri yok | |
| Independent Director | 10.3yrs | US$272.49k | 0.087% $ 14.6k | |
| Independent Director | 1.3yrs | US$376.01k | 0% $ 0 | |
| Independent Director | 4.4yrs | US$262.49k | 0.094% $ 15.7k | |
| Independent Director | 2yrs | US$254.99k | 0.059% $ 9.9k |
5.3yrs
Ortalama Görev Süresi
61.5yo
Ortalama Yaş
Deneyimli Yönetim Kurulu: CARA 'nin yönetim kurulu üyeleri deneyimli olarak kabul edilir (ortalama görev süresi 5.3 yıldır).